Navigating Treatment Failure in CML
|Navigating Treatment Failure in CML|
Stuart L. Goldberg, MD
|Release Date: October 09, 2015|
Expiration Date: October 09, 2016
Patients with chronic myelogenous leukemia (CML) who are treated with first-generation TKIs have a 90% chance of surviving for at least five years following initiation of treatment. Nevertheless, a significant number of CML patients experience treatment failure, which is associated with increased risk of disease progression and reduced survival. This interactive case study will use a decision-tree format to explore several critical aspects of CML management that can contribute to treatment failure. By making clinical decisions as the case progresses from diagnosis to treatment and monitoring, learners will gain a greater understanding of approaches that may be used to reduce the risk of treatment failure in CML and to support improved outcomes in these patients.Provided by MediCom Worldwide, Inc.
This activity is supported by an unrestricted educational grant from Teva Pharmaceuticals.
MediCom Worldwide, Inc. acknowledges the collaborative support from The Leukemia & Lymphoma Society.
|View Only, CE Expired|